BRAF and melanoma: (MALAT1/GAPDH TPM in GTEx: 0.52 vs. TCGA: 0.01, Figure 4A) Specifically, MALAT1 showed a significant 63-fold decrease in patient-derived NRAS- and BRAF-mutated melanoma (p < 0.001, Figure 4A) These findings are particularly noteworthy as previous analyses in smaller sample sizes of melanoma and adjacent normal tissues showed significant overexpression of MALAT1 in melanoma [12, 52].